Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
Exciting results in the clinical trial Plenary at #AANAM2026.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
Join me, @drjmartindale.bsky.social and @rohitmarawar.bsky.social this afternoon at 2pm at Leadership University for our session on AI augmented leadership! #AANAM2026
